Related references
Note: Only part of the references are listed.Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
Charlotte-Paige Rolle et al.
AIDS (2021)
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice
Arturo Ciccullo et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2020)
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
Jean van Wyk et al.
CLINICAL INFECTIOUS DISEASES (2020)
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
Pedro Cahn et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
Jasper Fuk-Woo Chan et al.
LANCET (2020)
The challenge of HIV treatment in an era of polypharmacy
David Back et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2020)
Drug hypersensitivity in HIV infection
Jonny Peter et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients
Gianmaria Baldin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Alberto Borghetti et al.
BMC INFECTIOUS DISEASES (2019)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn et al.
LANCET (2019)
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients
Arturo Ciccullo et al.
ANTIVIRAL THERAPY (2019)
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication
A. Borghetti et al.
HIV MEDICINE (2018)
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M. Llibre et al.
LANCET (2018)
CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV
Win Min Han et al.
AIDS RESEARCH AND THERAPY (2018)
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance
Bluma G. Brenner et al.
VIRUS RESEARCH (2017)
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Pedro Cahn et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2017)
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
Federico Pulido et al.
CLINICAL INFECTIOUS DISEASES (2017)
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Adam Trickey et al.
CLINICAL INFECTIOUS DISEASES (2017)
Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
Sean G. Kelly et al.
DRUGS (2016)
Rapid and Slow Progressors Show Increased IL-6 and IL-10 Levels in the Pre-AIDS Stage of HIV Infection
Rubia M. de Medeiros et al.
PLOS ONE (2016)
Persistent HIV-1 replication during antiretroviral therapy
Javier Martinez-Picado et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection
R. Chris Rathbun et al.
ANNALS OF PHARMACOTHERAPY (2014)
Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
Grace A. McComsey et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection
Peter W. Hunt et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviraltherapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Pedro Cahn et al.
LANCET INFECTIOUS DISEASES (2014)
Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients
Getnet Yimer et al.
PLOS ONE (2014)
HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality
Sergio Serrano-Villar et al.
PLOS PATHOGENS (2014)
Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
Mackenzie L. Cottrell et al.
CLINICAL PHARMACOKINETICS (2013)
Systemic Effects of Inflammation on Health during Chronic HIV Infection
Steven G. Deeks et al.
IMMUNITY (2013)
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Hasina Samji et al.
PLOS ONE (2013)
CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy
Mohamed-Rachid Boulassel et al.
JOURNAL OF CLINICAL VIROLOGY (2012)
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min et al.
AIDS (2011)
Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration
Dai Watanabe et al.
BMC INFECTIOUS DISEASES (2011)
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
Catia Marzolini et al.
ANTIVIRAL THERAPY (2010)
Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients
Marianne Burgard et al.
AIDS (2009)
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
Jason M. Brenchley et al.
NATURE MEDICINE (2006)
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
A Mocroft et al.
LANCET (2003)
Neuropsychiatric complications of nevirapine treatment
MEJ Wise et al.
BRITISH MEDICAL JOURNAL (2002)
Share Paper
